SG11202108767PA - Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells - Google Patents

Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells

Info

Publication number
SG11202108767PA
SG11202108767PA SG11202108767PA SG11202108767PA SG11202108767PA SG 11202108767P A SG11202108767P A SG 11202108767PA SG 11202108767P A SG11202108767P A SG 11202108767PA SG 11202108767P A SG11202108767P A SG 11202108767PA SG 11202108767P A SG11202108767P A SG 11202108767PA
Authority
SG
Singapore
Prior art keywords
amyloidosis
antibody
producing
treatment
combination
Prior art date
Application number
SG11202108767PA
Other languages
English (en)
Inventor
Raymond Comenzo
Wagner Zago
Nina Ashton
Original Assignee
Prothena Biosciences Ltd
Tufts Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Tufts Medical Ct Inc filed Critical Prothena Biosciences Ltd
Publication of SG11202108767PA publication Critical patent/SG11202108767PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202108767PA 2019-02-12 2019-12-16 Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells SG11202108767PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962804721P 2019-02-12 2019-02-12
PCT/US2019/066648 WO2020167376A1 (en) 2019-02-12 2019-12-16 Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells

Publications (1)

Publication Number Publication Date
SG11202108767PA true SG11202108767PA (en) 2021-09-29

Family

ID=69182616

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108767PA SG11202108767PA (en) 2019-02-12 2019-12-16 Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells

Country Status (16)

Country Link
US (1) US20220213223A1 (zh)
EP (1) EP3923954A1 (zh)
JP (1) JP2022520572A (zh)
KR (1) KR20210143752A (zh)
CN (1) CN113924099A (zh)
AU (1) AU2019429147A1 (zh)
BR (1) BR112021015870A2 (zh)
CA (1) CA3129890A1 (zh)
CL (1) CL2021002140A1 (zh)
EA (1) EA202192235A1 (zh)
IL (1) IL285480A (zh)
JO (1) JOP20210220A1 (zh)
MA (1) MA54923A (zh)
MX (1) MX2021009687A (zh)
SG (1) SG11202108767PA (zh)
WO (1) WO2020167376A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220019656A (ko) 2019-03-05 2022-02-17 프로테나 바이오사이언시즈 리미티드 경쇄 아밀로이드증 치료 방법
US20220049009A1 (en) 2020-07-23 2022-02-17 Othair Prothena Limited Anti-Abeta Antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
SI2567976T1 (sl) 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
PT2237803E (pt) 2007-12-28 2015-10-16 Prothena Biosciences Ltd Tratamento e profilaxia da amiloidose
LT2580243T (lt) 2010-06-09 2020-01-27 Genmab A/S Antikūnai prieš žmogaus cd38
IN2014CN03555A (zh) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
EP2771033A4 (en) 2011-10-28 2016-02-17 Integritybio Inc PROTEIN FORMULATIONS CONTAINING AMINO ACIDS
AU2016264725B2 (en) 2015-05-20 2021-05-27 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
MA53356B1 (fr) 2015-11-03 2022-05-31 Janssen Biotech Inc Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
DK3478713T3 (da) * 2016-06-30 2022-06-20 Prothena Biosciences Ltd Sammensætninger til behandling af amyloidose

Also Published As

Publication number Publication date
EA202192235A1 (ru) 2022-01-19
BR112021015870A2 (pt) 2021-11-03
CL2021002140A1 (es) 2022-04-18
AU2019429147A1 (en) 2021-09-09
JP2022520572A (ja) 2022-03-31
JOP20210220A1 (ar) 2023-01-30
CA3129890A1 (en) 2020-08-20
MX2021009687A (es) 2021-12-10
IL285480A (en) 2021-09-30
MA54923A (fr) 2021-12-22
WO2020167376A8 (en) 2020-10-29
KR20210143752A (ko) 2021-11-29
US20220213223A1 (en) 2022-07-07
WO2020167376A1 (en) 2020-08-20
EP3923954A1 (en) 2021-12-22
CN113924099A (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
IL285480A (en) Treatment of al amyloidosis in combination with monoclonal antibodies against immunoglobulin light chains and cell membrane molecule cd38 on antibody-producing cells and other immune system cells
IL266230A (en) Antibodies directed against t-cell immunoglobulin and mucin protein 3 (tim-3)
JOP20180042A1 (ar) نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
PH12019502785A1 (en) Anti trbc1 antigen binding domains
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
WO2018013818A3 (en) Antibodies against tim3 and uses thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
HRP20200034T1 (hr) Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
MX2020005792A (es) Anticuerpo anti-pd-l1/anti-cd47 biespecifico con estructura tipo anticuerpo natural y en forma de heterodimero y preparacion del mismo.
CO6251371A2 (es) Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino
RU2013140350A (ru) Антитела против человеческого il33r и их применение
RU2017129721A (ru) АНТИТЕЛА ПРОТИВ αβTCR
SG11202009283QA (en) Humanized bcma antibody and bcma-car-t cells
EP4063498A4 (en) OXA-23 TYPE CARBAPENEMASE RESISTANT HYBRIDOMA CELL LINE AND USE OF MONOCLONAL ANTIBODIES (MAB) THEREOF
EA202190608A1 (ru) Однодоменные анти-bcma антитела и их применение
EP3919512A4 (en) HUMANIZED ANTI-Abeta MONOCLONAL ANTIBODY AND USE
AR102042A1 (es) ANTICUERPO CONTRA INMUNOGLOBULINAS b (ANTI Igb HUMANA)
EP4056586A4 (en) REGULATORY T CELL SURFACE ANTIGEN EPITOPE, AND ANTIBODIES BINDING SPECIFICALLY THEREFOR
MX2022002505A (es) Anticuerpo monoclonal anti-cd47 y uso del mismo.
EP3901171A4 (en) HUMAN ANTI-TIM-3 MONOCLONAL ANTIBODY AND USE THEREOF
MX2021015763A (es) Polipeptidos.
EP3955925A4 (en) HUMANIZED ANTI-PD-L1 ANTIBODIES
EP3784700A4 (en) HIGH AFFINITY MONOCLONAL ANTIBODIES (MABs) TO HUMAN CELL SURFACE-EXPRESSED CARBON ANHYDRASE IX (HCA-IX), AND USES THEREOF